-
Fierce Biotech2 weeks ago
Biopharma funding dropped 20% in 2025 as companies doubled down on big bets: IQVIA
Biopharma funding fell 20% last year, reversing the post-pandemic recovery as the IPO haul dropped to the lowest level of the past 10 years, according to...
-
Fierce Biotech2 weeks ago
Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
Innate Pharma has finally called time on a NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.
-
Fierce Biotech2 weeks ago
FDA approves Denali’s Hunter syndrome drug, handing rare disease community a win
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates.
-
Fierce Biotech2 weeks ago
After ph. 2 readout, analysts herald ‘best-in-class potential’ for Maze kidney candidate as stock plummets
Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” But many investors were racing...
-
Fierce Biotech2 weeks ago
Takeda targets $1.3B in cost savings in further restructuring
Takeda is setting the stage for a sweeping new round of restructuring, aiming to streamline operations to bankroll upcoming drug launches and late-stage pipeline development.
-
Fierce Biotech2 weeks ago
Endogenex nets $50M to carry intestinal diabetes procedure to the FDA
The fundraising comes after clinical results showed its system met safety goals and led to metabolic improvements in HbA1c, fasting glucose levels and body weight.
-
Fierce Biotech2 weeks ago
Sarepta’s big bet on Arrowhead’s siRNA assets yields early data
Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead...
-
Fierce Biotech2 weeks ago
Novo Nordisk prepares to go global as triple-G prospect passes midphase diabetes test in China
Novo Nordisk and its Chinese partner have reported another midphase win for their triple G candidate, sharing diabetes data to add to the momentum generated by...
-
Fierce Biotech2 weeks ago
BrightGene’s oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data
China’s BrightGene has served up a slice of early-stage data to remind everyone that it has a horse in the oral obesity race.
-
Fierce Biotech2 weeks ago
Icon, Advarra partnership aims to optimize trials, expand access
Clinical research organization Icon has entered into a partnership with research technology company Advarra to launch a network of connected sites for clinical trials.
Terns rebuffed a higher bid before selling to Merck
